Acetylcholine receptor subunit alpha-1 (CHRNA1) (CHRNA1)

The Acetylcholine receptor subunit alpha-1 (CHRNA1) is a vital component of the muscle-type nicotinic acetylcholine receptor (nAChR) found at the neuromuscular junction. It functions as a ligand-gated ion channel that mediates the transmission of nerve impulses from motor neurons to skeletal muscle fibers, initiating contraction. When acetylcholine binds to the alpha-1 subunits, the channel opens to allow the influx of sodium ions, which depolarizes the muscle membrane [1][2]. This receptor is the primary target of autoantibodies in Myasthenia Gravis, a condition characterized by muscle weakness and fatigue [5]. Clinically, CHRNA1 is the target for neuromuscular blocking agents used during surgery to provide muscle relaxation and facilitate intubation [3]. Although the provided name included the term "neuronal," CHRNA1 is specifically the muscle-type subunit, whereas neuronal nAChRs are composed of subunits alpha-2 through alpha-10 [1][4].

Other names

ACHRACHRNANicotinic acetylcholine receptor subunit alpha 1Muscle-type nicotinic acetylcholine receptor subunit alphaCholinergic receptor nicotinic alpha 1 subunit

The mechanism of action involves binding to the alpha-1 subunits of the nicotinic receptor at the neuromuscular junction. Non-depolarizing agents act as competitive antagonists, blocking acetylcholine from binding and preventing muscle contraction [3]. Depolarizing agents act as agonists that cause persistent activation and subsequent desensitization of the receptor, leading to paralysis [4].